2008
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement
2000
p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis E. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clinical Biochemistry 2000, 33: 53-62. PMID: 10693987, DOI: 10.1016/s0009-9120(99)00084-3.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsP53 gene mutationsP53 protein accumulationAntibody-negative patientsP53 antibodiesSeronegative patientsGene mutationsP53 accumulationBreast cancerProportion of patientsPrimary breast cancerFormer patient groupP53 protein overexpressionPatient groupAutoantibody generationProtein accumulationImmune responseSuch antibodiesDirect DNA sequencingCorresponding tumorsPatientsImmunofluorometric assayGene abnormalitiesCancerP53 geneShorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer
Yu H, Bharaj B, Vassilikos E, Giai M, Diamandis E. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Research And Treatment 2000, 59: 153-161. PMID: 10817350, DOI: 10.1023/a:1006356502820.Peer-Reviewed Original ResearchConceptsBreast cancerAndrogen receptorAggressive formCAG repeatsPositive lymph nodesPrimary breast cancerRisk of deathAR transcriptional activityImpact of androgensPatients' overall survivalAction of androgensBreast cancer tissuesBreast cancer progressionAndrogen receptor geneLength of CAGLong CAG repeatsOverall survivalLymph nodesPathological variablesPatient survivalHistological gradeHomozygous womenProstate cancerMean CAGDisease features
1999
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Foekens J, Diamandis E, Yu H, Look M, Gelder M, Putten W, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal Of Cancer 1999, 79: 888-894. PMID: 10070886, PMCID: PMC2362687, DOI: 10.1038/sj.bjc.6690142.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPostmenopausePredictive Value of TestsPremenopauseProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival AnalysisTamoxifenTime FactorsConceptsLevels of PSAProstate-specific antigenPrimary breast cancerRecurrent breast cancerBreast tumor cytosolsBreast cancerRecurrent diseaseEnzyme-linked immunosorbent assayTamoxifen therapyPoor responseTumor cytosolsAge/menopausal statusFirst-line tamoxifen therapyHormone receptor-negative tumorsSteroid hormone receptor statusDisease-free intervalSite of relapseCox multivariate analysisHormone receptor statusReceptor-negative tumorsClassical prognostic factorsPost-menopausal patientsRate of relapseBreast cancer patientsStart of treatment
1998
Insulin‐like growth factor–binding protein‐3 and breast cancer survival
Yu H, Levesque M, Khosravi M, Papanastasiou‐Diamandi A, Clark G, Diamandis E. Insulin‐like growth factor–binding protein‐3 and breast cancer survival. International Journal Of Cancer 1998, 79: 624-628. PMID: 9842972, DOI: 10.1002/(sici)1097-0215(19981218)79:6<624::aid-ijc12>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorActions of IGFsIGFBP-3IGF-binding proteinsBreast cancer recurrenceS-phase fractionTumor sizeCancer recurrenceBreast cancerInsulin-like growth factor-binding protein-3Elevated S-phase fractionHigher IGFBP-3 levelsInhibits breast cancer cell growthBreast cancer cell growthDiagnosis-matched patientsIGFBP-3 levelsUnfavourable prognostic featuresUnfavourable prognostic indicatorPrimary breast cancerEstrogen receptor expressionLarger tumor sizeRisk of deathBreast cancer survivalCase-control studyBreast tissue extractsPrognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research 1998, 4: 1489-97. PMID: 9626467.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBreast NeoplasmsCohort StudiesCytosolFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedPloidiesPrognosisProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneS PhaseSurvival AnalysisTime FactorsUnited StatesConceptsProstate-specific antigenPrimary breast cancerBreast cancerCohort studyPrognostic valueRelative riskBreast tumorsSteroid hormone receptor levelsLow S-phase fractionMeasurement of PSAPSA-negative patientsPSA-positive patientsPrognosis of patientsYounger patient ageHormone receptor levelsLarge cohort studyUnited States cohort studyValuable tumor markerS-phase fractionUnited States patientsBreast tumor extractsMedian followPSA presenceNodal statusPatient age
1996
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorProstate-specific antigenIGFBP-3IGF-IIBreast cancerS-phase fractionIGFBP-1Prognostic indicatorGrowth factorActive insulin-like growth factorsHER-2/neu proteinUnfavourable prognostic indicatorPrimary breast cancerEpidermal growth factor receptorSteroid hormone receptorsTumor tissue cytosolGrowth factor receptorIGF functionEstrogen receptorDNA ploidyPossible associationNeu proteinCancerTissue cytosolsHormone receptors